HK Stock MarketDetailed Quotes
02367 GIANT BIOGENE
- 52.100
- -0.450-0.86%
Trading Nov 28 09:34 CST
53.57BMarket Cap27.65P/E (TTM)
52.550High51.800Low99.40KVolume52.550Open52.550Pre Close5.18MTurnover0.01%Turnover Ratio33.44P/E (Static)1.03BShares58.00052wk High8.19P/B53.57BFloat Cap27.78052wk Low0.97Dividend TTM1.03BShs Float58.000Historical High0.970Dividend LFY1.43%Amplitude23.180Historical Low52.070Avg Price200Lot Size1.86%Div YieldTTM1.86%Div Yield LFY
GIANT BIOGENE Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|
| Turnover | 58.21%2.54B | 49.05%3.52B | --1.61B | 52.30%2.36B | 30.41%1.55B | 24.44%1.19B | --956.7M |
| Operating income | 58.21%2.54B | 49.05%3.52B | 1.61B | 52.30%2.36B | 30.41%1.55B | 24.44%1.19B | 956.7M |
| Cost of sales | -75.57%-447.19M | -56.28%-577.01M | ---254.7M | -86.33%-369.21M | -8.04%-198.15M | -14.64%-183.41M | ---159.99M |
| Operating expenses | -75.57%-447.19M | -56.28%-577.01M | -254.7M | -86.33%-369.21M | -8.04%-198.15M | -14.64%-183.41M | -159.99M |
| Gross profit | 54.94%2.09B | 47.71%2.95B | 1.35B | 47.32%2B | 34.48%1.35B | 26.40%1.01B | 796.71M |
| Selling expenses | -60.67%-892.02M | -64.86%-1.16B | ---555.18M | -104.03%-706.37M | -118.54%-346.21M | -68.91%-158.42M | ---93.79M |
| Administrative expenses | -38.26%-65.65M | 12.98%-96.66M | ---47.48M | -53.68%-111.07M | -119.07%-72.27M | -14.38%-32.99M | ---28.85M |
| Research and development expenses | -43.20%-48.7M | -70.22%-74.97M | ---34.01M | -76.50%-44.04M | -86.49%-24.95M | -17.38%-13.38M | ---11.4M |
| Impairment and provision | -247.59%-490K | 214.01%700K | --332K | -88.34%-614K | -113.15%-326K | 342.09%2.48M | ---1.02M |
| -Other impairment is provision | -247.59%-490K | 214.01%700K | --332K | -88.34%-614K | -113.15%-326K | 342.09%2.48M | ---1.02M |
| Special items of operating profit | 12.93%68.87M | 199.11%133.49M | --60.98M | -28.41%44.63M | -63.00%62.35M | 998.29%168.49M | --15.34M |
| Operating profit | 48.94%1.16B | 48.18%1.75B | 775.64M | 21.06%1.18B | -0.03%972.92M | 43.76%973.24M | 677M |
| Financing cost | 5.26%-54K | -433.33%-112K | ---57K | ---21K | ---- | ---- | ---- |
| Earning before tax | 48.94%1.16B | 48.17%1.75B | 775.58M | 21.05%1.18B | -0.03%972.92M | 43.76%973.24M | 677M |
| Tax | -59.40%-174.64M | -68.53%-296.89M | ---109.56M | -21.67%-176.16M | 1.34%-144.79M | -44.14%-146.76M | ---101.82M |
| After-tax profit from continuing operations | 47.22%980.55M | 44.59%1.45B | 666.02M | 20.95%1B | 0.20%828.13M | 43.69%826.49M | 575.18M |
| Earning after tax | 47.22%980.55M | 44.59%1.45B | 666.02M | 20.95%1B | 0.20%828.13M | 43.69%826.49M | 575.18M |
| Minority profit | -185.06%-2.61M | -708.88%-3.55M | ---917K | ---439K | ---- | -99.85%35K | --22.92M |
| Profit attributable to shareholders | 47.41%983.16M | 44.88%1.45B | 666.94M | 21.00%1B | 0.20%828.13M | 49.65%826.45M | 552.26M |
| Basic earnings per share | 47.76%0.99 | 50.51%1.49 | 0.67 | 19.28%0.99 | 0.00%0.83 | 50.91%0.83 | 0.55 |
| Diluted earnings per share | 46.97%0.97 | 51.02%1.48 | 0.66 | 18.07%0.98 | 0.00%0.83 | 50.91%0.83 | 0.55 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data